These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19433668)

  • 1. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis.
    Strober J; Cowan MJ; Horn BN
    Arch Neurol; 2009 May; 66(5):659-61. PubMed ID: 19433668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child.
    Saulat B; Maertens P; Hamilton WJ; Bassam BA
    Neurology; 2007 Aug; 69(8):803-4. PubMed ID: 17709714
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is cerebral involvement an occasional feature of muscle-specific kinase antibody-positive syndrome?
    Bhagavati S; Maccabee PJ; Chari G
    Eur J Neurol; 2007 Aug; 14(8):e21-2. PubMed ID: 17661994
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical features of patients with Myasthenia gravis from the Henan province, China.
    Gao F; Zhao X; Zhang J; Cui X; Zhang Y; Li Q; Liu P; Fang H; Du Y; Zhang Q; Yang J; Zhang Y
    Muscle Nerve; 2016 May; 53(5):711-6. PubMed ID: 26403759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different characteristic phenotypes according to antibody in myasthenia gravis.
    Oh SJ; Morgan MB; Lu L; Hatanaka Y; Hemmi S; Young A; Claussen GC
    J Clin Neuromuscul Dis; 2012 Dec; 14(2):57-65. PubMed ID: 23172384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
    Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
    Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to therapy in myasthenia gravis with anti-MuSK antibodies.
    Evoli A; Bianchi MR; Riso R; Minicuci GM; Batocchi AP; Servidei S; Scuderi F; Bartoccioni E
    Ann N Y Acad Sci; 2008; 1132():76-83. PubMed ID: 18567856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An atypical course of myasthenia gravis.
    Labana SS; Qureshi S; Nandakumar T; Cervellione KL; Venkatraman GK; Thakore H; Gintautas J
    Proc West Pharmacol Soc; 2007; 50():140-2. PubMed ID: 18605252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anti-acetylcholine receptor antibody in neonatal myasthenia gravis.
    Skoglund RR; Roberts CC; Huddlestone J
    Bull Los Angeles Neurol Soc; 1978; 43(2-4):66-9. PubMed ID: 757366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two.
    Schoser B; Jacob S; Hilton-Jones D; Müller-Felber W; Kubisch C; Claus D; Goebel HH; Vita G; Vincent A; Toscano A; Van den Bergh P
    Neuromuscul Disord; 2009 Mar; 19(3):223-8. PubMed ID: 19208478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular involvement in MuSK antibody-positive myasthenia gravis].
    Bau V; Hanisch F; Hain B; Zierz S
    Klin Monbl Augenheilkd; 2006 Jan; 223(1):81-3. PubMed ID: 16418940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report.
    Sossa Melo CL; Peña AM; Salazar LA; Jiménez SI; Gómez ED; Chalela CM; Ayala-Castillo M; Peña IM
    Neuromuscul Disord; 2019 Feb; 29(2):142-145. PubMed ID: 30639064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis crisis.
    Bershad EM; Feen ES; Suarez JI
    South Med J; 2008 Jan; 101(1):63-9. PubMed ID: 18176295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.